Fanvue | $22,000,000 | (Jan 20, 2026)
Dominion Dynamics | $15,200,000 | (Jan 20, 2026)
Tulip Interfaces | $120,000,000 | (Jan 20, 2026)
Eigen Therapeutics
United States
- Redwood City, CA
- 13/12/2022
- Seed
- $7,000,000
Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthy cells more resilient to treatment.
Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives.
- Industry Biotechnology Research
- Website https://www.eigentx.com/
- LinkedIn https://www.linkedin.com/company/eigentherapeutics/
Fleetzero | $43,000,000 | (Jan 20, 2026)
EXCIVA GmbH | $59,817,135 | (Jan 20, 2026)
Transition Metal Solutions | $6,000,000 | (Jan 20, 2026)
one • fıve | $16,320,500 | (Jan 20, 2026)
Anzen Industries | $2,283,975 | (Jan 20, 2026)
Gutology | $2,418,300 | (Jan 20, 2026)
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)